GENERAL8 Sept 2026
Buy Fortis Healthcare shares, says PL Capital; check target price, stock performance
Brokerage Prabhudas Lilladher has kept a 'Buy' rating on Fortis Healthcare with a ₹1,050 target, even after the Delhi High Court ordered a forensic probe into past promoter dealings. The firm says this probe won't affect Fortis' expansion or growth plans. For shareholders, it suggests an upside of about 16%, but it's one analyst's view, so consider your own risk before acting.
Key Statutory Highlights
- PL Capital has maintained a 'Buy' rating on Fortis Healthcare with a target price of ₹1,050 per share.
- The Delhi High Court last week ordered a forensic audit into alleged asset dissipation by former promoters; the brokerage says it won't impact Fortis' capex or expansion plans.
- Fortis shares have rallied nearly 66% in two years and were trading at ₹910.21 on BSE, with a market capitalisation of ₹68,716.29 crore.
Actionable Advice for Taxpayers / Founders:Before acting on this 'Buy' call, review your own investment goals and consult a registered financial advisor, since this is just one brokerage's opinion and markets carry risk.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: